Roble Belko & Company’s ResMed RMD Stock Holding History

Roble Belko & Company’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-874	Closed	-$55K	–	315
2016 Q2	$55K	Sell	874 -35	-4%	-$2.06K	0.03%	106
2016 Q1	$53K	Hold	909	–	–	0.03%	94
2015 Q4	$49K	Hold	909	–	–	0.03%	93
2015 Q3	$46K	Hold	909	–	–	0.03%	90
2015 Q2	$51K	Hold	909	–	–	0.03%	95
2015 Q1	$65K	Buy	+909	New	+$59K	0.04%	83

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Roble Belko & Company's RMD Position: Q3 2016 in Review

Roble Belko & Company sold out of ResMed (RMD) in Q3 2016, closing a stake of 874 shares — an estimated $55K sold.

Roble Belko & Company first reported a position in RMD in Q1 2015 and held it in 6 quarters. The position peaked at $65K in Q1 2015. 373 funds tracked by Wall St. Rank hold RMD as of Q3 2016.

Roble Belko & Company reported no remaining ResMed position as of Q3 2016 after selling out during the quarter.
Roble Belko & Company sold 874 ResMed shares in Q3 2016, an estimated $55K.
Roble Belko & Company first reported a position in ResMed in Q1 2015 and held it in 6 quarters.
Roble Belko & Company's ResMed position peaked at $65K in Q1 2015.
373 funds tracked by Wall St. Rank held ResMed as of Q3 2016.

Based on Roble Belko & Company's 13F filing for Q3 2016, filed 1 Nov 2016.